Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMMP NASDAQ:TIL NASDAQ:XLO NASDAQ:ZIVO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMMPPrima BioMed$0.37+2.3%$0.45$0.29▼$3.53$54.82M2.218.46 million shs58,091 shsTILInstil Bio$7.96+0.5%$8.18$5.67▼$35.00$53.98M1.9175,564 shs4,722 shsXLOXilio Therapeutics$8.48+2.0%$8.23$6.47▼$12.74$55.63M-0.1240,346 shs14,107 shsZIVOZIVO Bioscience$3.69+9.3%$3.31$1.11▼$19.65$15.32M0.073,575 shs664 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMMPPrima BioMed0.00%-3.43%-30.02%-21.84%-79.10%TILInstil Bio0.00%-1.86%-1.86%-3.53%-76.86%XLOXilio Therapeutics0.00%+7.92%-0.60%+8.49%-10.39%ZIVOZIVO Bioscience0.00%+20.33%-0.54%-59.22%-73.77%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMMPPrima BioMed$0.37+2.3%$0.45$0.29▼$3.53$54.82M2.218.46 million shs58,091 shsTILInstil Bio$7.96+0.5%$8.18$5.67▼$35.00$53.98M1.9175,564 shs4,722 shsXLOXilio Therapeutics$8.48+2.0%$8.23$6.47▼$12.74$55.63M-0.1240,346 shs14,107 shsZIVOZIVO Bioscience$3.69+9.3%$3.31$1.11▼$19.65$15.32M0.073,575 shs664 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMMPPrima BioMed0.00%-3.43%-30.02%-21.84%-79.10%TILInstil Bio0.00%-1.86%-1.86%-3.53%-76.86%XLOXilio Therapeutics0.00%+7.92%-0.60%+8.49%-10.39%ZIVOZIVO Bioscience0.00%+20.33%-0.54%-59.22%-73.77%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMMPPrima BioMed 1.75Reduce$5.501,378.49% UpsideTILInstil Bio 1.67Reduce$66.00729.04% UpsideXLOXilio Therapeutics 2.50Moderate Buy$28.00230.27% UpsideZIVOZIVO Bioscience 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ZIVO, TIL, IMMP, and XLO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/26/2026XLOXilio Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/8/2026XLOXilio Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)3/27/2026TILInstil Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMMPPrima BioMed$6.69M8.19N/AN/A$0.63 per share0.59TILInstil BioN/AN/AN/AN/A$16.79 per shareN/AXLOXilio Therapeutics$53.48M1.04N/AN/A$7.31 per share1.16ZIVOZIVO Bioscience$15.85K966.62N/AN/A($0.81) per share-4.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMMPPrima BioMed-$39.78MN/AN/AN/AN/AN/AN/AN/A9/2/2026 (Estimated)TILInstil Bio-$71.37M-$7.08N/AN/AN/AN/A-39.76%-22.38%8/12/2026 (Estimated)XLOXilio Therapeutics-$35.04M-$3.55N/AN/AN/A-58.52%-151.42%-27.61%8/13/2026 (Estimated)ZIVOZIVO Bioscience-$7.78M-$1.71N/AN/AN/AN/AN/A-2,240.92%9/2/2026 (Estimated)Latest ZIVO, TIL, IMMP, and XLO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026TILInstil Bio-$0.62-$0.62N/A-$0.62N/AN/A5/12/2026Q1 2026XLOXilio Therapeutics-$0.66-$0.58+$0.08-$0.58$8.52 million$12.65 million3/27/2026Q4 2025TILInstil Bio-$2.31-$1.21+$1.10-$1.21$1.90 millionN/A3/23/2026Q4 2025XLOXilio Therapeutics-$1.68-$0.85+$0.83$0.81$10.90 million$13.69 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIMMPPrima BioMedN/AN/AN/AN/AN/ATILInstil BioN/AN/AN/AN/AN/AXLOXilio TherapeuticsN/AN/AN/AN/AN/AZIVOZIVO BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMMPPrima BioMedN/A2.97N/ATILInstil Bio0.7739.8739.87XLOXilio TherapeuticsN/A3.593.59ZIVOZIVO BioscienceN/A0.170.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMMPPrima BioMed2.32%TILInstil Bio60.56%XLOXilio Therapeutics54.29%ZIVOZIVO Bioscience12.83%Insider OwnershipCompanyInsider OwnershipIMMPPrima BioMed3.07%TILInstil Bio47.00%XLOXilio Therapeutics7.45%ZIVOZIVO Bioscience48.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMMPPrima BioMed2,021147.37 million142.85 millionOptionableTILInstil Bio4106.78 million3.59 millionNo DataXLOXilio Therapeutics706.58 million6.09 millionNot OptionableZIVOZIVO Bioscience104.15 million2.91 millionNot OptionableZIVO, TIL, IMMP, and XLO HeadlinesRecent News About These CompaniesZIVO Bioscience (NASDAQ:ZIVO) Stock Price Crosses Above 50 Day Moving Average - Here's What HappenedJune 4, 2026 | americanbankingnews.comZivo Bioscience, Inc. Announces Transition to OTCID MarketplaceMay 12, 2026 | businesswire.comZivo Bioscience Inc. WtApril 11, 2026 | barrons.comZIVO Bioscience Provides Special Letter to ShareholdersMarch 27, 2026 | businesswire.comMaxim Group Reaffirms Their Hold Rating on Zivo Bioscience (ZIVO)December 15, 2025 | theglobeandmail.comZIVO Bioscience releases letter to shareholdersSeptember 14, 2025 | wattagnet.comWZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic BusinessesSeptember 10, 2025 | businesswire.comZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in PoultryJune 20, 2025 | businesswire.comUniversity of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in PoultryMay 7, 2025 | finance.yahoo.comUniversity of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in PoultryMay 6, 2025 | businesswire.comZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in PoultryFebruary 6, 2025 | businesswire.comZivo Bioscience issues new shares, raises $1.5 millionJanuary 28, 2025 | msn.comTuesday's Insider Activity: Top Buys and Sells in US Stocks RevealedJanuary 1, 2025 | investing.comZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian InfluenzaDecember 20, 2024 | businesswire.comZIVO Stock Earnings: Zivo Bioscience Reported Results for Q4 2023March 18, 2024 | investorplace.comHarmony Biosciences HoldingsMarch 4, 2024 | forbes.comRegencell Bioscience Holdings Ltd RGCFebruary 1, 2024 | morningstar.comMZIVO Bioscience Announces Uplisting to OTCQB MarketJanuary 29, 2024 | finance.yahoo.comIdeaya BiosciencesJanuary 18, 2024 | forbes.comDare Bioscience Inc DAREJanuary 14, 2024 | morningstar.comMNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines5 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 20263 Rare Earth Stocks That Win No Matter What China Does NextBy Bridget Bennett | May 24, 2026Is Everspin Technologies the Next AI Edge Breakout?By Thomas Hughes | May 18, 2026Costco’s Strong Quarter Still Leaves Investors With a Valuation ProblemBy Dan Schmidt | May 30, 2026Snowflake and the Snowballing Impact of its AI FlywheelBy Thomas Hughes | May 28, 2026ZIVO, TIL, IMMP, and XLO Company DescriptionsPrima BioMed NASDAQ:IMMP$0.37 +0.01 (+2.28%) As of 11:27 AM Eastern This is a fair market value price provided by Massive. Learn more.Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.Instil Bio NASDAQ:TIL$7.96 +0.04 (+0.52%) As of 11:23 AM Eastern This is a fair market value price provided by Massive. Learn more.Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.Xilio Therapeutics NASDAQ:XLO$8.48 +0.17 (+2.02%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.ZIVO Bioscience NASDAQ:ZIVO$3.69 +0.31 (+9.27%) As of 11:02 AM EasternZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Mission Control: Floating In SpaceX's Record-Breaking Orbit 3 Dividend Increases Investors Can Actually Trust SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Meta to Follow Alphabet's Footsteps? What an Equity Raise Could Mean Viasat's Orbiting Profits: Space Force Jackpot? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
